{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T08:13:29Z","timestamp":1778487209254,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017258","name":"Rajiv Gandhi Cancer Institute and Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017258","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.leukres.2026.108218","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T16:06:42Z","timestamp":1774714002000},"page":"108218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Response-adapted dasatinib de-escalation strategy compared to upfront Low-dose dasatinib: A prospective cohort study"],"prefix":"10.1016","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3100-558X","authenticated-orcid":false,"given":"Rohan","family":"Halder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4630-0207","authenticated-orcid":false,"given":"Reema","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3040-5968","authenticated-orcid":false,"given":"Sujay","family":"Rainchwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2676-9654","authenticated-orcid":false,"given":"Sakshi","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6946-5336","authenticated-orcid":false,"given":"Nakul","family":"Tikare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy","family":"Palatty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aakanksha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayank","family":"Soni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swapnil","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9009-1302","authenticated-orcid":false,"given":"Tribikram","family":"Panda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vipul","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rayaz","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narendra","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh","family":"Bhurani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.leukres.2026.108218_bib1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N. Engl. J. Med"},{"issue":"24","key":"10.1016\/j.leukres.2026.108218_bib2","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.leukres.2026.108218_bib3","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2026.108218_bib4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1200\/JGO.2015.002667","article-title":"Chronic myeloid leukemia in India","volume":"3","author":"Ganesan","year":"2017","journal-title":"J. Glob. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2026.108218_bib5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/PPO.0b013e31815b0df7","article-title":"Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment","volume":"13","author":"Jabbour","year":"2007","journal-title":"Cancer J."},{"issue":"1","key":"10.1016\/j.leukres.2026.108218_bib6","first-page":"281","article-title":"Dasatinib in chronic myeloid leukemia: a review","volume":"5","author":"Aguilera","year":"2009","journal-title":"Ther. Clin. Risk Manag"},{"issue":"1","key":"10.1016\/j.leukres.2026.108218_bib7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/cncr.32504","article-title":"Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"126","author":"Naqvi","year":"2020","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.leukres.2026.108218_bib8","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.clml.2023.05.009","article-title":"Low-dose dasatinib (50 mg daily) frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia: 5-year follow-up results","volume":"23","author":"Gener-Ricos","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"15","key":"10.1016\/j.leukres.2026.108218_bib9","doi-asserted-by":"crossref","first-page":"7051","DOI":"10.1200\/JCO.2017.35.15_suppl.7051","article-title":"Impact of dose reductions on 5-year efficacy in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) from DASISION","volume":"35","author":"Cortes","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.leukres.2026.108218_bib10","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood.V128.22.787.787","article-title":"Cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients with deep molecular response: results of the Euro-Ski trial","volume":"128","author":"Mahon","year":"2016","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.leukres.2026.108218_bib11","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/cncr.31357","article-title":"Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"124","author":"Naqvi","year":"2018","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.leukres.2026.108218_bib12","doi-asserted-by":"crossref","first-page":"6789","DOI":"10.1182\/blood-2022-169777","article-title":"Low dose dasatinib is not as active in a CML CP cohort enriched with intermediate\/high-risk CML chronic phase: a phase IIb multi-center trial","volume":"140","author":"Abraham","year":"2022","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.leukres.2026.108218_bib13","article-title":"Efficacy of low-dose dasatinib (50 mg) in chronic myeloid leukemia: chronic phase (CML-CP) in LMIC\u2014are we there yet?","volume":"43","author":"Tikare","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2026.108218_bib14","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.clml.2022.11.006","article-title":"Attenuated dose dasatinib in newly diagnosed chronic myeloid leukemia chronic phase patients in India","volume":"23","author":"Ahmed","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.leukres.2026.108218_bib15","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1182\/blood-2024-210857","article-title":"Real-world data of molecular response using different dosage of upfront generic dasatinib in chronic phase chronic myeloid leukemia: single-center experience from India","volume":"144","author":"Satadeve","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2026.108218_bib16","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.clml.2017.02.023","article-title":"Elderly patients with chronic myeloid leukemia benefit from a dasatinib dose as low as 20 mg","volume":"17","author":"Itamura","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"7","key":"10.1016\/j.leukres.2026.108218_bib17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/17474086.2019.1623666","article-title":"An alternative way\u2013tyrosine kinase inhibitor (TKI) de-escalation\u2013to discontinue TKIs in order to achieve treatment-free remission","volume":"12","author":"Kunbaz","year":"2019","journal-title":"Expert Rev. Hematol."},{"issue":"3","key":"10.1016\/j.leukres.2026.108218_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm10030515","article-title":"Dose optimization of tyrosine kinase inhibitors in chronic myeloid leukemia: a new therapeutic challenge","volume":"10","author":"Iurlo","year":"2021","journal-title":"J. Clin. Med"},{"issue":"7","key":"10.1016\/j.leukres.2026.108218_bib19","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","article-title":"De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial","volume":"6","author":"Clark","year":"2019","journal-title":"Lancet Haematol."},{"issue":"24","key":"10.1016\/j.leukres.2026.108218_bib20","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N. Engl. J. Med"},{"issue":"20","key":"10.1016\/j.leukres.2026.108218_bib21","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.leukres.2026.108218_bib22","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/ajh.26689","article-title":"Low-dose dasatinib 50 mg\/day versus standard-dose dasatinib 100 mg\/day as frontline therapy in chronic myeloid leukemia in chronic phase: a propensity score analysis","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2026.108218_bib23","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1182\/blood-2024-206740","article-title":"Response adapted dasatinib de-escalation strategy compared to upfront low-dose dasatinib: a prospective cohort study","volume":"144","author":"Singh","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2026.108218_bib24","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1016\/S2352-3026(17)30066-2","article-title":"De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial","volume":"4","author":"Clark","year":"2017","journal-title":"Lancet Haematol."},{"issue":"13","key":"10.1016\/j.leukres.2026.108218_bib25","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.3390\/cancers17132148","article-title":"Real-world evidence of treatment-free remission strategies and outcomes in chronic myeloid leukemia","volume":"17","author":"Bourne","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.leukres.2026.108218_bib26","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/jha2.550","article-title":"De-escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: a multicentral, open-label, prospective trial in China","volume":"3","author":"Luo","year":"2022","journal-title":"EJHaem"},{"issue":"11","key":"10.1016\/j.leukres.2026.108218_bib27","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1038\/s41375-023-02028-2","article-title":"Survival with chronic myeloid leukaemia after failing milestones","volume":"37","author":"Lauseker","year":"2023","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.leukres.2026.108218_bib28","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1182\/blood.V118.21.4438.4438","article-title":"Dasatinib as a late second line therapy in chronic myeloid leukemia patients: a retrospective study from a tertiary care centre in India","volume":"118","author":"Seth","year":"2011","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T08:07:39Z","timestamp":1778486859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626000627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":28,"alternative-id":["S0145212626000627"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108218","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response-adapted dasatinib de-escalation strategy compared to upfront Low-dose dasatinib: A prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108218","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108218"}}